{"analyses":[{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.16","groupDescription":"Stratification factors: PD-L1 status, Bajorin risk score/presence of liver metastases, and investigator choice of chemotherapy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3968","paramType":"Hazard Ratio (HR)","paramValue":"0.98","statisticalComment":"one-sided","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.89","upperLimit":"15.61","value":"13.34"},{"groupId":"OG001","lowerLimit":"13.14","upperLimit":"17.68","value":"15.21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"359"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"description":"OS is defined as the time from randomization to death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Placebo+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Eligible participants received open-label atezolizumab as monotherapy.","id":"OG001","title":"Atezolizumab Monotherapy"}],"paramType":"MEDIAN","populationDescription":"The ITT population includes only participants concurrently enrolled in Stage 2 and only those who had been randomized at the time of approval of Protocol WO30070 v6.","reportingStatus":"POSTED","timeFrame":"Baseline until death due to any cause (up to approximately 73 months)","title":"Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm","type":"PRIMARY","unitOfMeasure":"Months"}